Prevalence of age-related macular degeneration in the United States.
David S. Friedman,O'Colmain Bj,Beatriz Munoz,Sandra C. Tomany,Catherine A. McCarty,de Jong Pt,de Jong Pt,de Jong Pt,Barbara Nemesure,Paul Mitchell,Paul Mitchell,John H. Kempen +11 more
TLDR
In this article, the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender was estimated.Citations
More filters
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Complement Factor H Polymorphism in Age-Related Macular Degeneration
Robert J. Klein,Caroline J. Zeiss,Emily Y. Chew,Jen-yue Tsai,Richard S. Sackler,Chad Haynes,A. K. Henning,John Paul SanGiovanni,Shrikant Mane,Susan T. Mayne,Michael B. Bracken,Frederick L. Ferris,Jurg Ott,Colin J. Barnstable,Josephine Hoh +14 more
TL;DR: A genome-wide screen for polymorphisms associated with age-related macular degeneration revealed a polymorphism in linkage disequilibrium with the risk allele representing a tyrosine-histidine change at amino acid 402 in the complement factor H gene.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan-Ling Wong,Xinyi Su,Xiang Li,Chui Ming Gemmy Cheung,Ronald Klein,Ching-Yu Cheng,Tien Yin Wong +6 more
TL;DR: In this article, the authors did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013, using retinal photographs and standardised grading classifications.
Journal ArticleDOI
Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning
Daniel S. Kermany,Daniel S. Kermany,Michael H. Goldbaum,Wenjia Cai,Carolina C. S. Valentim,Huiying Liang,Sally L. Baxter,Alex McKeown,Ge Yang,Xiaokang Wu,Fangbing Yan,Justin Dong,Made K. Prasadha,Jacqueline Pei,Jacqueline Pei,Magdalene Yin Lin Ting,Jie Zhu,Christina Li,Sierra Hewett,Sierra Hewett,Jason Dong,Ian Ziyar,Alexander Shi,Runze Zhang,Lianghong Zheng,Rui Hou,William Shi,Xin Fu,Xin Fu,Yaou Duan,Viet Anh Nguyen Huu,Viet Anh Nguyen Huu,Cindy Wen,Edward Zhang,Edward Zhang,Charlotte Zhang,Charlotte Zhang,Oulan Li,Oulan Li,Xiaobo Wang,Michael A Singer,Xiaodong Sun,Jie Xu,Ali Tafreshi,M. Anthony Lewis,Huimin Xia,Kang Zhang +46 more
TL;DR: A diagnostic tool based on a deep-learning framework for the screening of patients with common treatable blinding retinal diseases, which demonstrates performance comparable to that of human experts in classifying age-related macular degeneration and diabetic macular edema.
References
More filters
Journal ArticleDOI
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
TL;DR: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin (Visudyne) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration (AMD).
Journal ArticleDOI
An international classification and grading system for age-related maculopathy and age-related macular degeneration
Alan C. Bird,Neil M. Bressler,Susan B. Bressler,I H Chisholm,Gabriel Coscas,M.D. Davis,P.T.V.M. de Jong,Caroline C W Klaver,Barbara E.K. Klein,Ronald Klein,Philip B. Mitchell,J.P. Sarks,S.H. Sarks,Gisèle Soubrane,Hugh R. Taylor,Johannes R. Vingerling +15 more
TL;DR: A common detection and classification system is needed for epidemiologic studies of age-related maculopathy (ARM) and such a grading scheme for ARM is described in this paper.
Journal ArticleDOI
Prevalence of age-related maculopathy. The Beaver Dam Eye Study.
TL;DR: In this article, the relationship between retinal drusen, retinal pigmentary abnormalities, and macular degeneration to age and sex was studied in 4926 people between the ages of 43 and 86 years who participated in the Beaver Dam Eye Study.
Journal ArticleDOI
Prevalence of Age-related Maculopathy in Australia: The Blue Mountains Eye Study
TL;DR: Detailed prevalence rates for most components of ARM in an Australian population are provided and reinforce the Beaver Dam Eye Study findings for the relative age-specific frequency of age-related macular degeneration components.
Journal ArticleDOI
Age-Specific Prevalence and Causes of Blindness and Visual Impairment in an Older Population: The Rotterdam Study
TL;DR: The hierarchy of causes of blindness and visual impairment is highly determined by age; as yet, little can be done to reduce the exponential increase of blindness; however, adequate implementation of surgery to treat cataract could reduce visual impairment by one third.
Related Papers (5)
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
A. Kassoff,J. Kassoff,J. Buehler,M. Eglow,F. Kaufman,M. Mehu,S. Kieval,M. Mairs,B. Graig,A. Quattrocchi,David R. Jones,J. Locatelli,Alan J. Ruby,A Jr Capon,Bruce R. Garretson,Tarek S Hassan,Michael T. Trese,George A. Williams,V. Regan,P. Manatrey,P. Streasick,L. Szydlowski,F. McIver,C. Bridges,C. Stanley,K. Cumming,B. Lewis,Mary Zajechowski,R. R. Margherio,M. S. Cox,J. C. Werner,R. Falk,P. Siedlak,C. Neubert,Michael L. Klein,J. T. Stout,A. O'Malley,Andreas K. Lauer,Joseph E. Robertson,David J. Wilson,C. Beardsley,H. Anderson,P. Wallace,G. Smith,Shannon Howard,Richard F. Dreyer,C. Ma,R. G. Chenoweth,John Zilis,M. Johnson,Patrick B. Rice,H. Daniel,H. Crider,Stuart G Parker,K. Sherman,Daniel F. Martin,T M Sr Aaberg,P Jr Sternberg,Linda Curtis,B. Ju,James Gilman,B. Myles,S. Strittman,Christina Gentry,H. Yi,A Jr Capone,M. Lambert,Travis A. Meredith,T M Jr Aaberg,D. Saperstein,J. I. Lim,B. Stribling,D. Armiger,R. Swords,David H. Orth,T. P. Flood,J. Civantos,S. deBustros,Kirk H. Packo,Pauline T. Merrill,J. A. Cohen,Celeste Figliulo,Chris Morrison,D. A. Bryant,Don Doherty,M. McVicker,T. Drefcinski,J. M. Seddon,M. K. Pinnolis,N. Davis,I. Burton,T. Taitsel,David I. Walsh,J. Dubois-Moran,C. Callahan,Claudia Evans,K. K. Snow,D. A. Jones-Devonish,V. D. Crouse +98 more